Neurodegenerative disease research at RFUMS includes studies within the area of Alzheimer’s Disease
that focus on:
- Early neuronal pathology that occurs prior to the emergence of histopathology and cognitive decline (Beth Stutzmann)
- Use of gene transfer vectors to investigate specific gene functions in the brain as it relates to the disease(Bob Marr)
- Use of a proteomics-based approach to identify disease-specific biomarkers (Marc Glucksman)
- Use of antisense oligonucleotide technology and small molecule compounds for the treatment of spinal muscular atrophy, hearing impairment and Alzheimer's disease (Michelle Hastings).
- Discovery and development of small molecule therapeutics targeting novel targets or mechanisms in neurodegeneration (Russell Dahl).
Within the area of Parkinson’s Disease, research programs focus on:
- Effects of dysregulation of pre-mRNA splicing on progressive neurodegeneration (Judy Potashkin)
- Role of nitric oxide and dopamine interactions and related signaling pathways in the pathophysiology of this disease with the aim of identifying novel drug targets for treatment (Anthony West, Kuei Tseng)
- Molecular/cellular and behavioral effects resulting from altered gene expression due to dopamine depletion in Parkinson model rats (Heinz Steiner)
- Disease-related destruction of the dopaminergic system, focused on understanding the mechanisms that underlie levodopa-induced dyskinesias (Gloria Meredith).